{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T03:47:33Z","timestamp":1761709653094,"version":"3.40.5"},"reference-count":40,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T00:00:00Z","timestamp":1567641600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Diabetes Invest"],"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aims\/Introduction<\/jats:title><jats:p>This subanalysis aimed to assess the safety and effectiveness of tofogliflozin by using data from the Japanese Study of Tofogliflozin with Type 2 Diabetes Mellitus Patients in an Observational Study of the Elderly to categorize elderly Japanese patients with type\u00a02 diabetes mellitus by the number of concomitant oral antidiabetic drugs (OADs) and insulin use at baseline.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>Japanese Study of Tofogliflozin with Type 2 Diabetes Mellitus Patients in an Observational Study of the Elderly is a 1\u2010year prospective, observational and multicenter post\u2010marketing study that enrolled all patients with type\u00a02 diabetes mellitus aged \u226565\u00a0years who started tofogliflozin during the first 3\u00a0months after its launch in May 2014 in Japan.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The safety and effectiveness analysis sets included 1,497 and 1,422 patients, respectively. Overall, 18.10 and 2.20% of the patients experienced adverse drug reactions (ADRs) and serious ADRs, respectively. ADRs of special interest in the total, 0 OAD, one OAD, two OADs, three or more OADs and insulin groups occurred in 12.22, 10.04, 12.35, 13.32, 11.27 and 14.91% of patients, respectively. Volume depletion\u2010related events were the most frequently observed ADRs of special interest. Hypoglycemia occurred in 1.07% of patients. Overall, glycated hemoglobin and bodyweight were significantly decreased, but the estimated glomerular filtration rate was not significantly changed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our finding suggests that tofogliflozin could be safely and effectively used in elderly Japanese patients with type\u00a02 diabetes mellitus, irrespective of the number of OADs and the use of insulin.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdi.13125","type":"journal-article","created":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T13:28:45Z","timestamp":1565184525000},"page":"405-416","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Safety and effectiveness of tofogliflozin in elderly Japanese patients with type\u00a02 diabetes mellitus: A subanalysis of a post\u2010marketing study (J\u2010STEP\/EL Study)"],"prefix":"10.1111","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1574-0565","authenticated-orcid":false,"given":"Kohei","family":"Kaku","sequence":"first","affiliation":[{"name":"Department of Medicine Kawasaki Medical School Kurashiki Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Naito","sequence":"additional","affiliation":[{"name":"Diabetes &amp; Cardiovascular Medical Operations Sanofi K.K. Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6673-1429","authenticated-orcid":false,"given":"Masayuki","family":"Senda","sequence":"additional","affiliation":[{"name":"Medical Affairs Sanofi K.K. Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3464-0669","authenticated-orcid":false,"given":"Yuji","family":"Kurihara","sequence":"additional","affiliation":[{"name":"Post Marketing Surveillance Department Kowa Company, Ltd. Nagoya Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoji","family":"Gunji","sequence":"additional","affiliation":[{"name":"Post Marketing Surveillance Department Kowa Company, Ltd. Nagoya Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seigo","family":"Kakiuchi","sequence":"additional","affiliation":[{"name":"Post Marketing Surveillance Department Kowa Company, Ltd. Nagoya Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunori","family":"Utsunomiya","sequence":"additional","affiliation":[{"name":"Center for Preventive Medicine The Jikei University School of Medicine Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,9,5]]},"reference":[{"key":"e_1_2_7_2_1","unstructured":"Ministry of Health Labour and Welfare Japan.National Health and Nutrition Survey 2016. Available from:http:\/\/www.mhlw.go.jp\/file\/04-Houdouhappyou-10904750-Kenkoukyoku-Gantaisakukenkouzoushinka\/kekkagaiyou_7.pdf. Accessed March 27 2018. (Japanese)."},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.12035"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-013-0039-6"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.18632\/aging.100646"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-S014"},{"volume-title":"Treatment Guide for Diabetes Among the Elderly 2018","year":"2018","author":"The Japan Diabetes Society, the Japan Geriatrics Society","key":"e_1_2_7_7_1"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-013-0020-4"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.161.13.1629"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2011.03772.x"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.333.7559.143"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1R621"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-009-1179-2"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2012.07.019"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.112.191593"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0229-1"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2840-13-65"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2014.887680"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12538"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13213"},{"key":"e_1_2_7_21_1","unstructured":"SanofiKK.Risk management plan for Apleway 20\u00a0mg Tablet. December 2015 (in Japanese). Available from:https:\/\/e-mr.sanofi.co.jp\/-\/media\/EMS\/Conditions\/eMR\/di\/information\/apw_rmp01_201601.pdf?la=ja-JP. Accessed March 27 2018. (Japanese)."},{"key":"e_1_2_7_22_1","unstructured":"Kowa Company Ltd.Risk management plan for Deberza 20\u00a0mg Tablet. December 2015 (in Japanese). Available from:https:\/\/www.pmda.go.jp\/files\/000218003.pdf. Accessed March 27 2018. (Japanese)"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2015.1034105"},{"key":"e_1_2_7_24_1","unstructured":"InagakiN UekiK KakuK et\u00a0al.Recommendations for appropriate use of sodium\/glucose co\u2010transporter 2 inhibitors. 2016. Available from:http:\/\/www.fa.kyorin.co.jp\/jds\/uploads\/recommendation_SGLT2.pdf. Accessed March 27 2018. (Japanese)."},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12513"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12626"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2016.1219341"},{"key":"e_1_2_7_28_1","first-page":"357","article-title":"Investigation of the safety and efficacy of dapagliflozin for type 2 diabetes in elderly patients\u2010final report of the dapagliflozin observational study (DIANTHUS study)","volume":"45","author":"Yoshida S","year":"2017","journal-title":"Jpn Pharmacol Ther"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2017.1392293"},{"key":"e_1_2_7_30_1","first-page":"559","article-title":"Evaluation of the safety and efficacy of SGLT2 inhibitor luseogliflozin in elderly patients with type 2 diabetes mellitus\u2010post\u2010marketing surveillance in elderly patients (final report)","volume":"45","author":"Kurose T","year":"2017","journal-title":"Jpn Pharmacol Ther"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2018.1434145"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.12.2948"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2840-11-122"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.9400"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i2231"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-1630"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2013.356"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2015.10.025"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0169463"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjopharm.2008.11.001"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-0114"}],"container-title":["Journal of Diabetes Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdi.13125","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdi.13125","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdi.13125","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdi.13125","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T09:33:06Z","timestamp":1694079186000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdi.13125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,5]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["10.1111\/jdi.13125"],"URL":"https:\/\/doi.org\/10.1111\/jdi.13125","archive":["Portico"],"relation":{},"ISSN":["2040-1116","2040-1124"],"issn-type":[{"type":"print","value":"2040-1116"},{"type":"electronic","value":"2040-1124"}],"subject":[],"published":{"date-parts":[[2019,9,5]]},"assertion":[{"value":"2019-03-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}